Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis

Standard

Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. / Shahnaz Syed Abd Kadir, Sharifah; Christopeit, Maximilian; Wulf, Gerald; Wagner, Eva; Bornhauser, Martin; Schroeder, Thomas; Crysandt, Martina; Mayer, Karin; Jonas, Julia; Stelljes, Matthias; Badbaran, Anita; Ayuketang Ayuk, Francis; Triviai, Ioanna; Wolf, Dominik; Wolschke, Christine; Kröger, Nicolaus.

in: EUR J HAEMATOL, Jahrgang 101, Nr. 3, 09.2018, S. 305-317.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsätzeForschungBegutachtung

Harvard

Shahnaz Syed Abd Kadir, S, Christopeit, M, Wulf, G, Wagner, E, Bornhauser, M, Schroeder, T, Crysandt, M, Mayer, K, Jonas, J, Stelljes, M, Badbaran, A, Ayuketang Ayuk, F, Triviai, I, Wolf, D, Wolschke, C & Kröger, N 2018, 'Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis', EUR J HAEMATOL, Jg. 101, Nr. 3, S. 305-317. https://doi.org/10.1111/ejh.13099

APA

Vancouver

Bibtex

@article{ffcb251cd09e4b0e8f749836e3c3c96e,
title = "Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis",
abstract = "INTRODUCTION: Ruxolitinib is the first approved drug for treatment of myelofibrosis, but its impact of outcome after allogeneic stem cell transplantation (ASCT) is unknown.PATIENTS AND METHODS: We reported on 159 myelofibrosis patients (pts) with a median age of 59 years (r: 28-74) who received reduced intensity ASCT between 2000 and 2015 in eight German centers from related (n = 23), matched (n = 86) or mismatched (n = 50) unrelated donors. Forty-six (29{\%}) patients received ruxolitinib at any time point prior to ASCT. The median daily dose of ruxolitinib was 30 mg (range 10-40 mg) and the median duration of treatment was 4.9 months (range 0.4-39.1 months).RESULTS: Primary graft failure was seen in 2 pts (4{\%}) in the ruxolitinib and 3 (2{\%}) in the non-ruxolitinib group. Engraftment and incidence of acute GVHD grade II to IV and III/IV did not differ between groups (37{\%} vs 39{\%} and 19{\%} vs 28{\%}, respectively), nor did the non-relapse mortality at 2 years (23{\%} vs 23{\%}). A trend for lower risk of relapse was seen in the ruxolitinib group (9{\%} vs 17{\%}, P = .2), resulting in a similar 2 year DFS and OS (68{\%} vs 60{\%} and 73{\%} vs 70{\%}, respectively). No difference in any outcome variable could be seen between ruxolitinib responders and those who failed or lost response to ruxolitinib.CONCLUSIONS: These results suggest that ruxolitinib pretreatment in myelofibrosis patient does not negatively influence outcome after allogeneic stem cell transplantation.",
keywords = "Journal Article",
author = "{Shahnaz Syed Abd Kadir}, Sharifah and Maximilian Christopeit and Gerald Wulf and Eva Wagner and Martin Bornhauser and Thomas Schroeder and Martina Crysandt and Karin Mayer and Julia Jonas and Matthias Stelljes and Anita Badbaran and {Ayuketang Ayuk}, Francis and Ioanna Triviai and Dominik Wolf and Christine Wolschke and Nicolaus Kr{\"o}ger",
note = "{\circledC} 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2018",
month = "9",
doi = "10.1111/ejh.13099",
language = "English",
volume = "101",
pages = "305--317",
journal = "EUR J HAEMATOL",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis

AU - Shahnaz Syed Abd Kadir, Sharifah

AU - Christopeit, Maximilian

AU - Wulf, Gerald

AU - Wagner, Eva

AU - Bornhauser, Martin

AU - Schroeder, Thomas

AU - Crysandt, Martina

AU - Mayer, Karin

AU - Jonas, Julia

AU - Stelljes, Matthias

AU - Badbaran, Anita

AU - Ayuketang Ayuk, Francis

AU - Triviai, Ioanna

AU - Wolf, Dominik

AU - Wolschke, Christine

AU - Kröger, Nicolaus

N1 - © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2018/9

Y1 - 2018/9

N2 - INTRODUCTION: Ruxolitinib is the first approved drug for treatment of myelofibrosis, but its impact of outcome after allogeneic stem cell transplantation (ASCT) is unknown.PATIENTS AND METHODS: We reported on 159 myelofibrosis patients (pts) with a median age of 59 years (r: 28-74) who received reduced intensity ASCT between 2000 and 2015 in eight German centers from related (n = 23), matched (n = 86) or mismatched (n = 50) unrelated donors. Forty-six (29%) patients received ruxolitinib at any time point prior to ASCT. The median daily dose of ruxolitinib was 30 mg (range 10-40 mg) and the median duration of treatment was 4.9 months (range 0.4-39.1 months).RESULTS: Primary graft failure was seen in 2 pts (4%) in the ruxolitinib and 3 (2%) in the non-ruxolitinib group. Engraftment and incidence of acute GVHD grade II to IV and III/IV did not differ between groups (37% vs 39% and 19% vs 28%, respectively), nor did the non-relapse mortality at 2 years (23% vs 23%). A trend for lower risk of relapse was seen in the ruxolitinib group (9% vs 17%, P = .2), resulting in a similar 2 year DFS and OS (68% vs 60% and 73% vs 70%, respectively). No difference in any outcome variable could be seen between ruxolitinib responders and those who failed or lost response to ruxolitinib.CONCLUSIONS: These results suggest that ruxolitinib pretreatment in myelofibrosis patient does not negatively influence outcome after allogeneic stem cell transplantation.

AB - INTRODUCTION: Ruxolitinib is the first approved drug for treatment of myelofibrosis, but its impact of outcome after allogeneic stem cell transplantation (ASCT) is unknown.PATIENTS AND METHODS: We reported on 159 myelofibrosis patients (pts) with a median age of 59 years (r: 28-74) who received reduced intensity ASCT between 2000 and 2015 in eight German centers from related (n = 23), matched (n = 86) or mismatched (n = 50) unrelated donors. Forty-six (29%) patients received ruxolitinib at any time point prior to ASCT. The median daily dose of ruxolitinib was 30 mg (range 10-40 mg) and the median duration of treatment was 4.9 months (range 0.4-39.1 months).RESULTS: Primary graft failure was seen in 2 pts (4%) in the ruxolitinib and 3 (2%) in the non-ruxolitinib group. Engraftment and incidence of acute GVHD grade II to IV and III/IV did not differ between groups (37% vs 39% and 19% vs 28%, respectively), nor did the non-relapse mortality at 2 years (23% vs 23%). A trend for lower risk of relapse was seen in the ruxolitinib group (9% vs 17%, P = .2), resulting in a similar 2 year DFS and OS (68% vs 60% and 73% vs 70%, respectively). No difference in any outcome variable could be seen between ruxolitinib responders and those who failed or lost response to ruxolitinib.CONCLUSIONS: These results suggest that ruxolitinib pretreatment in myelofibrosis patient does not negatively influence outcome after allogeneic stem cell transplantation.

KW - Journal Article

U2 - 10.1111/ejh.13099

DO - 10.1111/ejh.13099

M3 - SCORING: Journal articles

C2 - 29791053

VL - 101

SP - 305

EP - 317

JO - EUR J HAEMATOL

JF - EUR J HAEMATOL

SN - 0902-4441

IS - 3

ER -